Phase 3 N=29 Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
Raynaud Phenomenon
Primary: RP Attacks Per Day — -0.5; -0.5 attacks per day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=3,029 Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
GERD
Primary: Efficacy of Three Strategies of Long-term Treatment — 10.6; 7.8; 43 Percentage of participants with failure
Phase 4 N=186 Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Intra-patient Accuracy (Percent Agreement), On-site Data — 77.1; 80.6 percentage of agreement
Phase 4 N=102 Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm
Atrial Fibrillation · Pulmonary Embolism · Deep Vein Thrombosis
Primary: In Patients Receiving Warfarin, a Pharmacogenetic Algorithm Dose Was Compared to Clinician Dosing (mg/wk). — 46.9; 35.4 mg/wk — p=< 0.05
Phase 4 N=17 Effect of Age on Latanoprost 0.005% in Patients With Glaucoma
Glaucoma
Primary: Pre-Treatment IOP (Intraocular Pressure) — 21.8 mm Hg
Phase 2 N=154 Tiotropium Respimat Pharmacokinetic Study in COPD
Pulmonary Disease, Chronic Obstructive
Primary: Maximum Plasma Concentration at Steady-state (Cmax,ss) — 2.81; 5.07; 10.5; 12.9 pg/ml — p=0.4423
Phase 2 N=611 Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain
Pain
Primary: Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing. — 36.7; 59.7; 55.6; 72.1 percentage of patients
Phase 2 N=98 Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
Pulmonary Diseases · Neoplasms, Lung
Primary: Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC). — 0; 0…
Phase 4 N=90 A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men
HPV Vaccine Acceptability
Primary: Change From Baseline to Post Intervention to Follow-up (up to 3 Months) After the Interventions the Number of Participants Who Have Taken the HPV Vaccine — 0; 0; 0; 0…
Phase 3 N=514 Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
Parkinson's Disease
Primary: The Change in the Absolute Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary — -1.948; -2.052; -2.138…
Phase 1 N=12 Co-Administration Of Methotrexate And CP-690,550
Rheumatoid Arthritis
Primary: Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)] for CP-690,550 — 1370; 1410 nanogram*hour/milliliter (ng*hr/mL)
Phase 4 N=91 A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
Rheumatoid Arthritis
Primary: Percentage of Participants Who Responded to ≥ 6 of 12 Anti-pneumococcal Antibody Serotypes — 70.8; 60.0 percentage of participants
Phase 3 N=3,366 Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
Arthritis, Rheumatoid
Primary: Number of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response at Month 6 — 2692 Participants
Phase 3 N=252 Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock
Septic Shock
Primary: Efficacy and Safety of Dopamine Versus Norepinephrine in Septic Shock — 67; 51 participants
Phase 3 N=51 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Eosinophilic Esophagitis · Gastroesophageal Reflux Disease · EE
Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00